18 August - Based on the data included in the New Drug Application for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults. The recommendation for approval, (16 voted for, one abstained from voting), was based on a global development programme involving more than 8,000 adults with type 2 diabetes in the eight SUSTAIN phase 3a clinical trials, including a cardiovascular outcomes trial.
“Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. We look forward to working with the FDA as they complete their review of semaglutide,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer.
29 September - In the US: Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved - in Europe: CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia and
27 September - in China: Novo Nordisk's new-generation basal insulin Tresiba® approved in China
1 October, Camilla Sylvest, senior vice president in charge of Novo Nordisk’s operations in Region China, started as executive vice president in charge of Commercial Strategy & Corporate Affairs. Camilla is overall responsible for the corporate functions in marketing, market access, strategy, communication, stakeholder relations and sustainability. Also, Doug Langa, senior vice president, head of North America Operations and president of Novo Nordisk Inc, has been promoted to executive vice president.
With millions displaced by war, business has a key role in helping refugees integrate, contribute and flourish in society. Each individual you meet has their own personal backstory of despair and upheaval. Days on end spent on an over-crowded boat, bobbing on the Mediterranean. Families fragmented and dispersed. Careers and livelihoods abruptly curtailed.
Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.
Novo Nordisk and Glooko will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. Read all the details
Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.
Contribution to a national life science strategy in Denmark from Novo Nordisk, Lundbeck and LEO Pharma.
Download the pdf
Read about our team of anthropologists that travelled to the US to take a closer look at digital health solutions. What they uncovered was that much more than health data is being shared in the digital ecosystem. And read more!
Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change.
The view on obesity is slowly changing, but there are still many myths about the disease that all contribute to creating barriers for proper treatment.